ATE406874T1 - Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden - Google Patents

Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden

Info

Publication number
ATE406874T1
ATE406874T1 AT05756461T AT05756461T ATE406874T1 AT E406874 T1 ATE406874 T1 AT E406874T1 AT 05756461 T AT05756461 T AT 05756461T AT 05756461 T AT05756461 T AT 05756461T AT E406874 T1 ATE406874 T1 AT E406874T1
Authority
AT
Austria
Prior art keywords
glycolipides
compositions
methods
based adjuvant
adjuvant formulations
Prior art date
Application number
AT05756461T
Other languages
English (en)
Inventor
Jesper Davidsen
Ida Rosenkrands
Peter Andersen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406874(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of ATE406874T1 publication Critical patent/ATE406874T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05756461T 2004-07-07 2005-07-05 Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden ATE406874T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200401070 2004-07-07

Publications (1)

Publication Number Publication Date
ATE406874T1 true ATE406874T1 (de) 2008-09-15

Family

ID=34982425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05756461T ATE406874T1 (de) 2004-07-07 2005-07-05 Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden

Country Status (16)

Country Link
EP (1) EP1765289B1 (de)
JP (1) JP4987704B2 (de)
KR (1) KR101275837B1 (de)
CN (1) CN1980638B (de)
AT (1) ATE406874T1 (de)
AU (1) AU2005259685B2 (de)
BR (1) BRPI0512757B8 (de)
CA (1) CA2572985C (de)
DE (1) DE602005009535D1 (de)
DK (1) DK1765289T3 (de)
ES (1) ES2315880T3 (de)
PL (1) PL1765289T3 (de)
PT (1) PT1765289E (de)
SI (1) SI1765289T1 (de)
WO (1) WO2006002642A2 (de)
ZA (1) ZA200701043B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000261A2 (en) * 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
ES2611924T3 (es) 2006-10-03 2017-05-11 Arbutus Biopharma Corporation Formulaciones que contienen lípidos
PL2167124T3 (pl) 2007-06-29 2012-12-31 Statens Seruminstitut Zastosowanie monomikoliloglicerolu (MMG) jako adiuwantu
US20110280930A1 (en) 2008-05-02 2011-11-17 Facundo Batista Products and methods for stimulating an immune response
PT2385980T (pt) * 2009-01-08 2018-06-26 Albert Einstein College Medicine Inc Vacinas bacterianas com glicolípidos do tipo ceramida associados à parede celular e utilização dos mesmos
CN102482666B (zh) * 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
JP5933538B2 (ja) * 2010-07-02 2016-06-08 インターベット インターナショナル ベー． フェー． エーリキア・カニスに対するワクチンおよび関連する方法
US20140112979A1 (en) 2011-07-04 2014-04-24 Statens Serum Institut Methods for producing liposomes
JP6182457B2 (ja) * 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
WO2013089152A1 (ja) * 2011-12-12 2013-06-20 協和発酵キリン株式会社 カチオン性脂質の組み合わせを含有する脂質ナノ粒子
JP2016175841A (ja) * 2013-08-02 2016-10-06 三郎 斎藤 リポソームと、細胞障害性ｔ細胞活性を誘導するワクチン組成物
BR112016005948A2 (pt) * 2013-09-19 2017-09-26 Zoetis Services Llc adjuvantes com base em óleo
CN106535933B (zh) * 2014-08-04 2021-09-17 日东电工株式会社 包含核受体配体的免疫诱导促进用组合物以及疫苗药物组合物
BR112018001318B1 (pt) * 2015-07-20 2023-11-14 Zoetis Services Llc Lipossoma livre de saponina, formulação adjuvante, composição de vacina, uso terapêutico de um componente antigênico e da formulação adjuvante e método para preparar o referido lipossoma
US12064480B2 (en) 2018-04-13 2024-08-20 Glaxosmithkline Biologicals Sa Immunigenic alpha-branched trehalose-diesters
CN114657147B (zh) * 2022-01-27 2023-12-01 安徽智飞龙科马生物制药有限公司 一种生物材料的保护剂及其应用
CN115068602B (zh) * 2022-08-22 2022-11-01 北京华诺泰生物医药科技有限公司 一种表面改性氧化铝的复合疫苗佐剂、制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108934A (en) * 1983-11-30 1992-04-28 Kabushiki Kaisha Toshiba Quantitative immunoassay utilizing liposomes
JP2714972B2 (ja) * 1988-02-02 1998-02-16 千葉製粉株式会社 リン脂質集合体用修飾剤、リン脂質小胞体用凝集防止剤、リン脂質小胞体用融合防止剤およびリン脂質膜用表面固定化剤
JPH03249561A (ja) * 1990-02-28 1991-11-07 Toshiba Corp 免疫分析試薬
JPH0482824A (ja) * 1990-07-23 1992-03-16 Nippon Oil & Fats Co Ltd リポソーム及び水中油型エマルション
JPH0616688A (ja) * 1992-06-30 1994-01-25 Nippon Oil & Fats Co Ltd 脂肪酸糖エステル
JP3884488B2 (ja) * 1993-03-10 2007-02-21 千葉製粉株式会社 オリゴ糖脂質
JP3329554B2 (ja) * 1993-03-10 2002-09-30 千葉製粉株式会社 乾燥小胞体
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
JPH0925287A (ja) * 1995-07-13 1997-01-28 Eisai Co Ltd 合成脂質
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9808268D0 (en) * 1998-04-17 1998-06-17 Imp College Innovations Ltd Compound
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
AU2002311616B2 (en) * 2001-06-25 2007-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparation of vesicles loaded with biological material and different uses thereof

Also Published As

Publication number Publication date
WO2006002642A2 (en) 2006-01-12
ZA200701043B (en) 2007-12-27
KR101275837B1 (ko) 2013-06-18
KR20070051847A (ko) 2007-05-18
AU2005259685A1 (en) 2006-01-12
CN1980638A (zh) 2007-06-13
JP4987704B2 (ja) 2012-07-25
CN1980638B (zh) 2011-10-12
CA2572985A1 (en) 2006-01-12
BRPI0512757A (pt) 2008-04-08
PL1765289T3 (pl) 2009-02-27
AU2005259685B2 (en) 2010-04-08
BRPI0512757B8 (pt) 2021-05-25
EP1765289B1 (de) 2008-09-03
SI1765289T1 (sl) 2009-02-28
CA2572985C (en) 2014-04-22
EP1765289A2 (de) 2007-03-28
DK1765289T3 (da) 2008-12-15
JP2008505131A (ja) 2008-02-21
ES2315880T3 (es) 2009-04-01
PT1765289E (pt) 2008-12-05
WO2006002642A3 (en) 2006-05-18
BRPI0512757B1 (pt) 2021-04-06
DE602005009535D1 (de) 2008-10-16

Similar Documents

Publication Publication Date Title
ATE406874T1 (de) Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden
WO2021155243A8 (en) Respiratory virus immunizing compositions
ATE272410T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
ATE503493T1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung
TW200642700A (en) Chemically defined stabiliser
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
RU2013114392A (ru) Маленькие липосомы для доставки кодирующей иммуноген рнк
MX358706B (es) Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
ME01965B (me) Stabilizatori za vakcine osušene zamrzavanjem
WO2011027257A3 (en) Pcsk9 vaccine
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
WO2007024941A3 (en) Polyvalent vaccine
WO2010019262A3 (en) Polyvalent vaccine
GB2386072A (en) Novel vaccine
MX2010009351A (es) Particulas similares a virus cristalizadas con azucar.
TW200510538A (en) Functionally reconstituted viral membranes containing adjuvant
ZA202101465B (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
PH12018500458A1 (en) Vlp stabilized vaccine compositions
EA201391456A1 (ru) ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
WO2011032108A3 (en) Formulation for room temperature stabilization of a live attenuated bacterial vaccine
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
ATE404174T1 (de) Impfstoff zur transmukosalen verabreichung
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
WO2003101482A3 (en) Liposome vaccine formulations for fin-fish

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1765289

Country of ref document: EP